Last reviewed · How we verify
Duragesic reference fentanyl TDS
Duragesic reference fentanyl TDS is a Synthetic opioid agonist Small molecule drug developed by University of Maryland, Baltimore. It is currently FDA-approved for Chronic pain in opioid-tolerant patients, Cancer pain, Severe chronic non-cancer pain. Also known as: Brand name fentanyl TDS.
Fentanyl is a synthetic opioid agonist that binds to mu-opioid receptors in the central nervous system to produce analgesia and sedation.
Fentanyl is a synthetic opioid agonist that binds to mu-opioid receptors in the central nervous system to produce analgesia and sedation. Used for Chronic pain in opioid-tolerant patients, Cancer pain, Severe chronic non-cancer pain.
At a glance
| Generic name | Duragesic reference fentanyl TDS |
|---|---|
| Also known as | Brand name fentanyl TDS |
| Sponsor | University of Maryland, Baltimore |
| Drug class | Synthetic opioid agonist |
| Target | Mu-opioid receptor (μ-OR) |
| Modality | Small molecule |
| Therapeutic area | Pain Management |
| Phase | FDA-approved |
Mechanism of action
Fentanyl activates mu-opioid receptors throughout the brain and spinal cord, inhibiting pain signal transmission and modulating pain perception. The transdermal delivery system (Duragesic patch) provides sustained-release fentanyl over 72 hours, maintaining steady-state plasma concentrations for chronic pain management. TDS (three times daily) dosing refers to the typical patch replacement schedule.
Approved indications
- Chronic pain in opioid-tolerant patients
- Cancer pain
- Severe chronic non-cancer pain
Common side effects
- Constipation
- Nausea
- Dizziness
- Somnolence
- Headache
- Respiratory depression
- Application site reactions
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Duragesic reference fentanyl TDS CI brief — competitive landscape report
- Duragesic reference fentanyl TDS updates RSS · CI watch RSS
- University of Maryland, Baltimore portfolio CI
Frequently asked questions about Duragesic reference fentanyl TDS
What is Duragesic reference fentanyl TDS?
How does Duragesic reference fentanyl TDS work?
What is Duragesic reference fentanyl TDS used for?
Who makes Duragesic reference fentanyl TDS?
Is Duragesic reference fentanyl TDS also known as anything else?
What drug class is Duragesic reference fentanyl TDS in?
What development phase is Duragesic reference fentanyl TDS in?
What are the side effects of Duragesic reference fentanyl TDS?
What does Duragesic reference fentanyl TDS target?
Related
- Drug class: All Synthetic opioid agonist drugs
- Target: All drugs targeting Mu-opioid receptor (μ-OR)
- Manufacturer: University of Maryland, Baltimore — full pipeline
- Therapeutic area: All drugs in Pain Management
- Indication: Drugs for Chronic pain in opioid-tolerant patients
- Indication: Drugs for Cancer pain
- Indication: Drugs for Severe chronic non-cancer pain
- Also known as: Brand name fentanyl TDS
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing